...
首页> 外文期刊>Nature clinical practice. Oncology >Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer
【24h】

Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer

机译:多种临床试验确定ER阳性乳腺癌最佳治疗策略的优势

获取原文
获取原文并翻译 | 示例
           

摘要

Interest in the clinical use of gene-expression profiles has increased tremendously in the past fewyears, and the prognostic and predictive value of genetic markers is an interesting matter of debate. In patients with breast cancer, the estrogen receptor {ER) protein is a strong predictive marker of response to endocrine therapy, because tumors that do not express ER do not respond to such therapy. ER expression, however, is not an infallible predictor of endocrine responsiveness; the recurrence rate for ER-positive (ER+) breast cancer in patients in whom the primary tumor was thought to be completely resected and who received adjuvant treatment with tamoxifen is approximately 30%.
机译:在过去的几年中,对基因表达谱的临床使用的兴趣已大大增加,并且遗传标记的预后和预测价值是一个有趣的辩论问题。在患有乳腺癌的患者中,雌激素受体(ER)蛋白是对内分泌治疗反应的强预测指标,因为不表达ER的肿瘤对这种治疗没有反应。然而,ER表达并不是内分泌反应性的可靠预测因子。据认为原发肿瘤已完全切除并接受他莫昔芬辅助治疗的患者中ER阳性(ER +)乳腺癌的复发率约为30%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号